• Applications & Products
  • Media Formulation
  • About InVitria
  • Contact Us
  • Terms
  • Privacy
  • Sitemap
Performance. Defined.
  • 1-800-916-8311 or Email Us
  • iconMy Account
  • iconView Cart
  • Applications & Products
    • Applications
      • Gene Therapy
      • Cell Therapy
      • T-Cell Immunotherapy
      • Vaccine Production
      • Antibody Production
      • Final Formulation
      • Food Science
    • Product Types
      • Blood-Free Cell Culture Media
      • Cell Culture Components
      • Insulin-Transferrin Supplements
      • Recombinant Albumin
      • Recombinant Transferrin
      • Recombinant Lysozyme
    • Products
      • Cellastim S – Recombinant human albumin
      • Exbumin® – Recombinant human albumin excipient
      • Optibumin – Recombinant human albumin
      • Optiferrin – Recombinant human transferrin
      • Lacromin – Recombinant human holo lactoferrin
      • ITS AF – Blood-free cell culture media supplement
      • ITSE + A – Blood-free cell culture media supplement
      • ITSE Animal-Free® – Blood-free cell culture media supplement
      • Lysobac – Recombinant human lysozyme
      • Leukemia Inhibitory Factor
      • OptiPEAK® HEK293t
      • OptiPEAK® T Lymphocyte XPR
      • OptiVERO®
      • OptiFRZ®
  • Media Formulation
  • About InVitria
  • News & Blog
  • Contact Us
  • Applications
  • Products
  • Contact Us
  • Home
  • InVitria Expands European and UK Footprint

InVitria Expands European and UK Footprint

Published on 6 December 2021

InVitria expands its operations in Europe and the UK to serve customer demand

 

InVitria announces an expansion of its global presence to ensure customer satisfaction while offering a local supply for European and UK customers. “We are pleased to announce that InVitria completed qualification of a facility to serve European and UK customers from its operations in Munich, Germany. Our customers in the vaccine, cell and gene therapy, and medical device markets are expanding and require an efficient and reliable supply chain to serve their growing demand,” said Artur Tkachev, EMEA Regional Manager for InVitria. Starting this week, InVitria’s product line of blood-free and chemically defined cell culture components and media will be available with faster and more reliable delivery times.

 

InVitria received regulatory approval for Exbumin, a recombinant human serum albumin to be used as an excipient in vaccines to improve stability and potency. The product is recognized as the first and only recombinant human serum albumin approved as an excipient in a vaccine licensed for use in the USA, Europe, the UK, and Japan. In addition, the company expanded its portfolio of high-performance and chemically defined cell culture media that do not contain serum or blood-derived components. These cell culture media formulations are GMP, manufactured at large scale, and are currently used for clinical manufacturing. As well as the cell culture media, all InVitria products will now be available by overnight delivery to Europe and the UK from InVitria’s operations in Munich, Germany. For more information on our recent move and what this means for our future research efforts, please visit www.invitria.com or contact us by emailing info@invitria.com.

 

InVitria is a global leader in development and manufacture of high-performance blood-free cell culture and recombinant protein products designed to improve biomanufacturing and facilitate faster approval of life-changing therapies. The company provides unparalleled high-performance solutions for elimination of human and animal serum-derived raw materials in clinical manufacturing and commercial production of cell and gene therapies, vaccines, regenerative medicine, and medical devices. InVitria adheres to the FDA, and EMA regulations and offers cGMP and ISO compliant manufacturing capabilities scaled to meet growing global demand for chemically defined production of biologics.

 

 

Place your order today via InVitria.com or info@invitria.com to benefit from next day shipping

Start New Search

Quick Search Links

Application:

Antibody Production

Cell Therapy

Final Formulation

Food Science

Gene Therapy

T-Cell Immunotherapy

Vaccine Production

Product Category:

Cell Culture Supplements

Albumin

Cell Culture Media

Lactoferrin

LIF

Lysozyme

Single Components

Transferrin

Product:

Cellastim S® – Recombinant human albumin

Exbumin® – Recombinant human albumin excipient

ITS AF™ – Blood-free cell culture media supplement

ITSE + A™ – Blood-free cell culture media supplement

ITSE Animal-Free® – Blood-free cell culture media supplement

Lacromin® – Recombinant human holo-lactoferrin

Leukemia Inhibitory Factor

Lysobac® – Recombinant human lysozyme

Optibumin® – Recombinant human albumin

Optiferrin® – Recombinant human transferrin

OptiFRZ® – DMSO-Free Cryopreservation Medium

OptiPEAK® HEK293t

OptiPEAK® T Lymphocyte XPR

OptiVERO®

Document Type:

Application Notes

Blog

Interviews

Journal Articles (DOI Links)

News

Posters

Product Brochures

Product Specifications

SDS

Use Guidelines

Webinar

White Papers

Cell Line:

B Lymphocyte

CHO

ESC

HEK293

Hematopoetic Stem Cells

Hybridoma

iPSC

Mesenchymal Stem Cells

Natural Killer Cells

Neural Stem Cells

T Lymphocyte

VERO

  • 2718 Industrial Drive • Junction City, KS 66441
  • 800-916-8311
  • © 2022 InVitria

    • Terms
    • Privacy
    • Sitemap